The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial

AIM: The role of surgical castration and rosuvastatin treatment on lipid profile and lipid metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC) patients. METHODS: A total of 84 newly diagnosed castrated mPC patients treated with castration we...

Descripción completa

Detalles Bibliográficos
Autores principales: Karkeet, Riham M., Zekri, Abdelrahman N., Sayed-Ahmed, Mohamed M., Sherif, Ghada M., Salem, Salem E., Abdelbary, Ahmed, Fouad, Mariam A., Saad, Sherif Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731457/
https://www.ncbi.nlm.nih.gov/pubmed/36480560
http://dx.doi.org/10.1371/journal.pone.0278282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731457/
https://www.ncbi.nlm.nih.gov/pubmed/36480560
http://dx.doi.org/10.1371/journal.pone.0278282

Ejemplares similares